Vanguard Group Inc. Has $25.78 Million Stake in Esperion Therapeutics, Inc. (NASDAQ:ESPR)

Vanguard Group Inc. cut its stake in shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR) by 10.2% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 11,715,748 shares of the biopharmaceutical company’s stock after selling 1,327,329 shares during the quarter. Vanguard Group Inc. owned approximately 5.95% of Esperion Therapeutics worth $25,775,000 as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in ESPR. Geode Capital Management LLC raised its position in shares of Esperion Therapeutics by 4.1% during the third quarter. Geode Capital Management LLC now owns 4,331,314 shares of the biopharmaceutical company’s stock worth $7,148,000 after acquiring an additional 171,609 shares during the last quarter. State Street Corp raised its holdings in Esperion Therapeutics by 2.7% during the 3rd quarter. State Street Corp now owns 3,854,314 shares of the biopharmaceutical company’s stock worth $6,360,000 after purchasing an additional 99,802 shares during the last quarter. JPMorgan Chase & Co. raised its holdings in Esperion Therapeutics by 1.0% during the 3rd quarter. JPMorgan Chase & Co. now owns 2,069,117 shares of the biopharmaceutical company’s stock worth $3,414,000 after purchasing an additional 19,588 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. lifted its position in shares of Esperion Therapeutics by 31.0% in the 4th quarter. Connor Clark & Lunn Investment Management Ltd. now owns 932,008 shares of the biopharmaceutical company’s stock worth $2,050,000 after purchasing an additional 220,730 shares during the period. Finally, Wellington Management Group LLP boosted its stake in shares of Esperion Therapeutics by 66.8% in the 3rd quarter. Wellington Management Group LLP now owns 602,936 shares of the biopharmaceutical company’s stock valued at $995,000 after purchasing an additional 241,512 shares during the last quarter. Institutional investors own 47.39% of the company’s stock.

Esperion Therapeutics Stock Performance

Shares of NASDAQ:ESPR opened at $1.00 on Tuesday. Esperion Therapeutics, Inc. has a 52-week low of $0.93 and a 52-week high of $3.94. The business’s 50 day simple moving average is $1.56 and its two-hundred day simple moving average is $2.02. The firm has a market cap of $197.67 million, a P/E ratio of -1.56 and a beta of 0.86.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on ESPR. JMP Securities restated a “market outperform” rating and issued a $4.00 target price (down previously from $7.00) on shares of Esperion Therapeutics in a report on Tuesday, February 11th. Needham & Company LLC reissued a “buy” rating and issued a $5.00 price objective on shares of Esperion Therapeutics in a research note on Tuesday, April 8th. The Goldman Sachs Group began coverage on Esperion Therapeutics in a research note on Wednesday, December 18th. They set a “neutral” rating and a $4.00 target price for the company. HC Wainwright reissued a “buy” rating and issued a $16.00 price target on shares of Esperion Therapeutics in a research note on Thursday, March 20th. Finally, Cantor Fitzgerald began coverage on Esperion Therapeutics in a report on Tuesday, December 17th. They set an “overweight” rating and a $8.00 price target on the stock. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and four have assigned a buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $6.58.

Esperion Therapeutics Profile

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.